Fatty-acid binding protein 4 (FABP4), also termed adipocyte fatty-acid binding protein (A-FABP), or aP2, is a novel adipocyte-expressed factor which accounted for ~6% of total cellular proteins. Several animal experiments suggested that FABP4 plays a key role in the link between obesity and various features of metabolic syndrome [1]. Mice with targeted disruption of FABP4 accompany FABP5 almost completely to protect against diet-induced obesity, insulin resistance, dyslipidemia, type 2 diabetes, and fatty liver disease [2]. Studies in human found FABP4 serum levels were significantly increased in overweight and obese subjects, which predicted the risk to develop a metabolic syndrome and type 2 diabetes [3-4]. Additionally, serum FABP4 levels were associated with nonalcoholic fatty liver disease, carotid atherosclerosis and coronary artery disease [5-7].

Recombinant full-length human FABP4 in E.coli.

The antibody detects human FABP4. Not yet tested in other species.

Protein G affinity purification

Liquid in phosphate-buffered saline (PBS).

Store at –20°C for less than one week. For long-term storage, aliquot and freeze at -70°C. Avoid repeated freeze/defrost cycles.

This antibody can be used as a capture antibody in a human FABP4 ELISA.

[1] Makowski L, et al. (2004) J Nutr. 134: 2464S–2468S.

[2] Makowski L, et al. (2001) Nat Med. 7: 699–705.

[3] Xu A, et al. (2006). Clin Chem. 52(3):405-13.

[4] Xu A, et al. (2007). Circulation. 115:1537–1543.

[5] Rhee EJ, et al. (2009) Eur J Endocrinol. 160(2):165-72.

[6] Tso AW, et al. (2007) Diabetes Care. 30(10):2667-72

[7] J. Hyun Koh, et al. (2009) Diabetes Care. 32(1): 147 - 152.